Abstract
We have investigated the effects of the statins atorvastatin and fluvastatin on the cytochrome P450 3A4 enzyme (CYP 3A4)-mediated metabolism of midazolam in vitro, using pooled human liver microsomes. Midazolam was metabolised by human hepatic microsomes with a Michaelis-Menten constant (K(m)) of 5.25 (SD 1.2) micromol.l(-1). Atorvastatin was a moderate competitive inhibitor of CYP 3A4 with an inhibitory constant (K(i)) of 12.4 (95% CI 4.65-20.06) micromol.l(-1). Fluvastatin was a weak non-competitive inhibitor of CYP 3A4 with a K(i) of 94.3 (95% CI 55.01-133.5) micromol.l(-1). Both atorvastatin and fluvastatin inhibit the CYP 3A4-mediated metabolism of midazolam in vitro.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Atorvastatin
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme Inhibitors*
-
Cytochrome P-450 Enzyme System / physiology
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Enzyme Inhibitors / pharmacology
-
Fatty Acids, Monounsaturated / pharmacology*
-
Fluvastatin
-
Heptanoic Acids / pharmacology*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
-
Hypnotics and Sedatives / pharmacokinetics
-
In Vitro Techniques
-
Indoles / pharmacology*
-
Microsomes, Liver / metabolism
-
Midazolam / pharmacokinetics*
-
Pyrroles / pharmacology*
Substances
-
Cytochrome P-450 Enzyme Inhibitors
-
Enzyme Inhibitors
-
Fatty Acids, Monounsaturated
-
Heptanoic Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypnotics and Sedatives
-
Indoles
-
Pyrroles
-
Fluvastatin
-
Cytochrome P-450 Enzyme System
-
Atorvastatin
-
CYP3A protein, human
-
Cytochrome P-450 CYP3A
-
Midazolam